A. Hurley

发表

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy.

A. Trkola, J. Moore, D. Ho, 1999, The Journal of clinical investigation.

Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10

H. Katinger, T. Wrin, C. Petropoulos, 2004, Journal of Virology.

Decay characteristics of HIV-1-infected compartments during combination therapy

Alan S. Perelson, A. Perelson, D. Ho, 1997, Nature.

A Novel Antiviral Intervention Results in More Accurate Assessment of Human Immunodeficiency Virus Type 1 Replication Dynamics and T-Cell Decay In Vivo

Alan S. Perelson, A. Perelson, D. Ho, 2003, Journal of Virology.

Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA.

M A Nowak, M. Nowak, D. Ho, 1998, Science.

Primary HIV-1 Infection Is Associated with Preferential Depletion of CD4+ T Lymphocytes from Effector Sites in the Gastrointestinal Tract

Christine Hogan, Amir Horowitz, Klara Tenner-Racz, 2004, The Journal of experimental medicine.

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Ron Diskin, Beatrix Ueberheide, Michael S. Seaman, 2011, Science.

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

M. Nussenzweig, P. Bieniasz, A. West, 2020, Cell.

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies

M. Nussenzweig, P. Bieniasz, A. West, 2020, bioRxiv.

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.

Dynamics of Intermittent Viremia during Highly Active Antiretroviral Therapy in Patients Who Initiate Therapy during Chronic versus Acute and Early Human Immunodeficiency Virus Type 1 Infection

A. Perelson, D. Ho, D. Follmann, 2004, Journal of Virology.

Title Phase I safety and immunogenicity evaluation of ADVAX , aMultigenic , DNA-based Clade C / B ' HIV-1 candidate vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010 .

Plasma microRNA Interindividual Variability in Healthy Individuals, Pregnant Women, and an Individual with a Stably Altered Neuroendocrine Phenotype.

T. Tuschl, A. Hurley, K. Max, 2021, Clinical chemistry.

Detection of circulating extracellular mRNAs by modified small RNA-sequencing analysis

T. Tuschl, M. Borggrefe, M. Neurath, 2018, bioRxiv.

Public broadly neutralizing antibodies against hepatitis B virus in individuals with elite serologic activity

C. Rice, M. Nussenzweig, A. Hurley, 2020, bioRxiv.

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

C. Rice, M. Nussenzweig, A. Hurley, 2020, Cell host & microbe.

Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico

C. Rice, M. Nussenzweig, A. West, 2017, Cell.

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers

A. Hurley, D. Lyden, T. Keler, 2015, Bone Marrow Transplantation.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeﬁciency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, X. Jin, 2002 .

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

M. Nussenzweig, P. Bieniasz, A. Hurley, 2021, Nature.

Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals

C. Rice, M. Nussenzweig, P. Bieniasz, 2020, bioRxiv.

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

C. Rice, M. Nussenzweig, P. Bieniasz, 2020, Nature.

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

M. Nussenzweig, P. Bieniasz, A. Hurley, 2021, bioRxiv.

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection.

D. Ho, A. Hurley, M. Markowitz, 1995, The New England journal of medicine.

Human Immunodeficiency Virus Type 1 Induces Persistent Changes in Mucosal and Blood γδ T Cells despite Suppressive Therapy

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of Virology.

Evolution of antibody immunity to SARS-CoV-2

M. Nussenzweig, P. Bieniasz, A. Hurley, 2021, Nature.

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis

Sebastian Bonhoeffer, Alan S Perelson, John E Mittler, 1999, The Lancet.

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection.

D. Ho, A. Hurley, M. Markowitz, 1998, The Journal of infectious diseases.

HIV-1 drug resistance in newly infected individuals.

Y. Cao, L. Zhang, A. Hurley, 1999, JAMA.

Detection of circulating extracellular mRNAs by modified small RNA-sequencing analysis

T. Tuschl, M. Borggrefe, M. Neurath, 2018, bioRxiv.

Evolution of Antibody Immunity to SARS-CoV-2

M. Nussenzweig, P. Bieniasz, A. Hurley, 2020, bioRxiv.

Determining the relative efficacy of highly active antiretroviral therapy.

Christine Hogan, Alan S Perelson, A. Perelson, 2003, The Journal of infectious diseases.

Use of Real-Time PCR and Molecular Beacons To Detect Virus Replication in Human Immunodeficiency Virus Type 1-Infected Individuals on Prolonged Effective Antiretroviral Therapy

D. Ho, L. Zhang, A. Hurley, 1999, Journal of Virology.

Effective Antiretroviral Therapy 1-Infected Individuals on Prolonged Human Immunodeficiency Virus Type Beacons To Detect Virus Replication in Use of Real-Time PCR and Molecular

L. Zhang, A. Hurley, M. Markowitz, 1999 .

Identification of Novel Therapeutic Targets for Fibrolamellar Carcinoma Using Patient Derived Xenografts and Direct from Patient Screening.

A. Letai, C. Rice, A. Hurley, 2021, Cancer discovery.

Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.

D. Ho, X. Jin, L. Zhang, 2000, The Journal of clinical investigation.

Virologic and immunologic effect of antiretroviral therapy on HIV-1 in gut-associated lymphoid tissue.

A. Hurley, M. Vesanen, A. Talal, 2001 .

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.

J. Moore, D. Ho, J. Binley, 1999, The Journal of infectious diseases.

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

Jill Gilmour, Sandhya Vasan, D. Ho, 2011, PloS one.

Persistent cellular immunity to SARS-CoV-2 infection

M. Nussenzweig, A. Hurley, Thiago Y. Oliveira, 2021, The Journal of experimental medicine.

Persistent Cellular Immunity to SARS-CoV-2 Infection

M. Nussenzweig, A. Hurley, Thiago Y. Oliveira, 2020, bioRxiv.

Decay Kinetics of Human Immunodeficiency Virus-Specific Effector Cytotoxic T Lymphocytes after Combination Antiretroviral Therapy

M. Nowak, D. Ho, Y. Cao, 1999, Journal of Virology.

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein

Lynn Morris, Yan Liu, Michael S. Seaman, 2012, The Journal of experimental medicine.

Human immunodeficiency virus type 1 induces persistent changes in mucosal and blood gammadelta T cells despite suppressive therapy.

D. Ho, A. Hurley, M. Markowitz, 2003, Journal of virology.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

Yang Song, Soe Than, Martin Ho, 2010, PloS one.

Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination.

A. Perelson, D. Ho, A. Hurley, 2002, The Journal of infectious diseases.

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

A. Trkola, D. Richman, J. Moore, 2000, The Journal of infectious diseases.

HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy

D. Ho, J. Binley, John P. Moore, 1998, The Journal of experimental medicine.

The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy

Alan S. Perelson, John E. Mittler, Catherine A. Macken, 2000, Nature Medicine.

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals

Richard T. Wyatt, Michael S. Seaman, John R. Mascola, 2009, Nature.

Virologic and Immunologic Effect of Antiretroviral Therapy on HIV‐1 in Gut‐Associated Lymphoid Tissue

A. Hurley, M. Vesanen, A. Talal, 2001, Journal of acquired immune deficiency syndromes.

Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals

A. Hurley, N. Parkin, V. Simon, 2002, AIDS.

Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals

Christine Hogan, Alan S Perelson, A. Perelson, 2003, AIDS.

Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in Newly Human Immunodeficiency Virus Type 1-Infected Patients Treated with Prolonged Highly Active Antiretroviral Therapy

D. Ho, J. Binley, A. Hurley, 2002, Journal of Virology.

Highly Active Antiretroviral Therapy 1-Infected Patients Treated with Prolonged Human Immunodeficiency Virus Type vCP 1452 and Recombinant gp 160 in Newly Safety and Immunogenicity of ALVAC

D. Ho, J. Binley, A. Hurley, 2002 .

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

C. Rice, M. Nussenzweig, P. Bieniasz, 2020, Nature.

Viral Blip Dynamics during Highly Active Antiretroviral Therapy

Alan S. Perelson, Christine Hogan, A. Perelson, 2003, Journal of Virology.

The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.

J. Moore, J. Binley, G. M. Ortiz, 2000, The Journal of infectious diseases.

Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.

J. Moore, A. Hurley, M. Markowitz, 2000, AIDS research and human retroviruses.

Intensification of Antiretroviral Therapy Accelerates the Decay of the HIV-1 Latent Reservoir and Decreases, But Does Not Eliminate, Ongoing Virus Replication

Alan S Perelson, A. Perelson, D. Ho, 2004, Journal of acquired immune deficiency syndromes.

A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers

A. Hurley, T. Keler, M. Yellin, 2012 .

Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

D. Ho, S. Furlan, A. Hurley, 2001 .

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

M. Nussenzweig, P. Bieniasz, A. Hurley, 2021, Nature.

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.

A. Perelson, B. Korber, D. Ho, 1999, The New England journal of medicine.

Phase 1 Safety and Immunogenicity Evaluation of ADVAX, a Multigenic, DNA-Based Clade C/B' HIV-1 Candidate Vaccine

D. Ho, Zhiwei Chen, A. Hurley, 2010, PloS one.